800 SW Jackson, Suite 1414
Topeka, Kansas 66612-1244
www.pharmacy.ks.gov (785)296-4056
STATEWIDE PROTOCOL:
Urinary Tract Infection
Page 3 of 6
Revised 6/14/2023
Patients who do not qualify for CLIA-waived testing under this Protocol shall be referred by the pharmacist to a primary
care provider or urgent/emergent treatment facility as clinically appropriate. Patients who do not qualify for antibiotic
dispensing following testing will be referred for additional evaluation when the pharmacist has high suspicion of a false-
negative result, determines that the patient is at high risk for complications, or otherwise considers additional care to be
in the best interest of the patient.
The pharmacist shall provide counseling to any patient being assessed, tested, and/or treated pursuant to this Protocol
on all the following:
• Instructions on when to seek medical attention, including:
o Symptoms that do not resolve or worsen after three days;
o Development of a fever (temperature ≥100.4 F, taken orally); or
o Flank pain;
• Medication counseling pursuant to K.A.R. 68-2-20;
• Counseling on the importance of adherence to an antibiotic regimen and completion of the entire course; and
• Counseling regarding prevention of UTIs, including signs and symptoms that warrant emergency medical care.
3. Procedures for Testing and Initiation of Therapy
The pharmacist shall assess the patient’s relevant medical and social history:
• Patient demographics
• Medical history
• Relevant social history
• Current clinical comorbidities or disease states, including current mental status
• Current blood pressure, pulse, oxygen saturation, respiratory rate, temperature, and weight
• For females of child-bearing potential: pregnancy and breastfeeding status
• Current medications
• Medication allergies and hypersensitivities (pharmacist shall assess reported allergies for validity by reviewing
the patient’s pharmacy record, if applicable, and documenting the reported reaction)
• Onset and duration of signs and symptoms
If the patient qualifies for CLIA-waived testing under this Protocol, then the pharmacist shall perform a CLIA-waived
point-of-care test to determine the patient’s UTI status.
• If positive, the pharmacist may proceed to consideration for antibiotic therapy treatment.
• If negative, the pharmacist shall counsel the patient on the risk of a false-negative test result and on appropriate
self-care (get plenty of rest, drink plenty of fluids, treat symptoms as needed, etc.) or shall refer the patient to a
primary care provider or urgent/emergency treatment facility as clinically appropriate.
The pharmacist shall evaluate for contraindications and precautions:
• Allergic reaction, hypersensitivity, or contraindication to a treatment listed in this Protocol
• Renal insufficiency (nitrofurantoin monohydrate/macrocrystals and phenazopyridine)
• Previous UTI treatment failure
• History of chronic kidney disease (i.e., creatinine clearance (CrCl) < 60 ml/min, reduced kidney function, etc.)